Published in Proc Natl Acad Sci U S A on August 12, 2002
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol (2007) 2.59
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev (2004) 1.55
Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun (2006) 1.50
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog (2015) 1.41
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr Top Microbiol Immunol (2012) 1.28
Neutralising antibodies against ricin toxin. PLoS One (2011) 1.26
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Monoclonal antibody therapies against anthrax. Toxins (Basel) (2011) 1.19
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg Med Chem Lett (2007) 1.19
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One (2008) 1.11
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun (2005) 1.10
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors. J Med Chem (2010) 1.08
Antibody to ricin a chain hinders intracellular routing of toxin and protects cells even after toxin has been internalized. PLoS One (2013) 1.06
Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A (2003) 1.05
Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun (2009) 1.05
Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One (2010) 1.03
The staphylococcal enterotoxin (SE) family: SEB and siblings. Virulence (2013) 1.02
Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun (2009) 1.02
Antibodies for biodefense. MAbs (2011) 1.02
Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One (2010) 1.01
Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal Chem (2015) 1.00
Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel (2010) 0.99
A fluorescence detection platform using spatial electroluminescent excitation for measuring botulinum neurotoxin A activity. Biosens Bioelectron (2008) 0.99
High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs (2013) 0.99
Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One (2010) 0.97
Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem (2012) 0.93
Developement of serum-free media in CHO-DG44 cells using a central composite statistical design. Cytotechnology (2007) 0.93
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther (2012) 0.92
Tumor detection by imaging proteolytic activity. Cancer Res (2010) 0.92
Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One (2011) 0.92
The quorum quenching antibody RS2-1G9 protects macrophages from the cytotoxic effects of the Pseudomonas aeruginosa quorum sensing signalling molecule N-3-oxo-dodecanoyl-homoserine lactone. Mol Immunol (2008) 0.91
A neutralizing antibody to the a chain of abrin inhibits abrin toxicity both in vitro and in vivo. Clin Vaccine Immunol (2008) 0.91
Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine (2012) 0.91
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs (2014) 0.91
Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther (2010) 0.91
Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem (2011) 0.90
Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun (2015) 0.90
Multi-wavelength Spatial LED illumination based detector for in vitro detection of Botulinum Neurotoxin A Activity. Sens Actuators B Chem (2010) 0.90
Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett (2014) 0.90
Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action. Clin Vaccine Immunol (2012) 0.89
Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun (2009) 0.89
Lab-on-a-chip for botulinum neurotoxin a (BoNT-A) activity analysis. Lab Chip (2009) 0.89
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel) (2010) 0.88
Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov (2009) 0.88
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron (2009) 0.87
Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments. Toxicon (2013) 0.86
Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies. Toxins (Basel) (2013) 0.86
Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng (2013) 0.86
Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN). Toxins (Basel) (2015) 0.86
Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) (2011) 0.86
Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin. J Infect Dis (2014) 0.85
Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A. PLoS One (2010) 0.85
Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One (2012) 0.85
Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol (2011) 0.85
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med (2013) 0.84
Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharm (2011) 0.84
Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis (2016) 0.84
Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother (2014) 0.83
Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infect Immun (2013) 0.83
Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther (2011) 0.83
Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem (2012) 0.82
Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding. Mol Immunol (2010) 0.82
DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge. Hum Vaccin Immunother (2015) 0.81
Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B. Clin Vaccine Immunol (2010) 0.81
On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity. Adv Bioinformatics (2012) 0.81
Enhancing the protective immune response against botulism. Infect Immun (2013) 0.81
The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs (2014) 0.80
Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One (2015) 0.79
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs. Toxins (Basel) (2015) 0.79
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel) (2015) 0.79
Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS One (2016) 0.79
Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin A1. Toxins (Basel) (2012) 0.78
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs (2015) 0.78
Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein. PLoS One (2011) 0.78
A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques. Exp Mol Pathol (2014) 0.78
Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine (2013) 0.78
Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor. Mol Immunol (2013) 0.77
Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A. Hybridoma (Larchmt) (2011) 0.77
Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol (2015) 0.76
Epitope mapping of botulinum neurotoxins light chains. Toxicon (2012) 0.76
A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. MAbs (2016) 0.76
Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS One (2014) 0.76
A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality. Hum Vaccin Immunother (2015) 0.75
Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library. Toxins (Basel) (2016) 0.75
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature (1992) 8.39
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol (1998) 4.21
Bacterial toxins: a table of lethal amounts. Microbiol Rev (1982) 3.74
Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem (1993) 2.79
The influence of polyvalency on the binding properties of antibodies. Immunochemistry (1972) 2.67
Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys (1995) 2.57
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun (1997) 2.53
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
PREPARATION AND ASSAY OF THE INTERNATIONAL STANDARDS FOR CLOSTRIDIUM BOTULINUM TYPES A, B, C, D AND E ANTITOXINS. Bull World Health Organ (1963) 2.30
Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature (1984) 2.02
Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol (1999) 1.98
Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther (1980) 1.79
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun (1997) 1.77
Hypersensitivity reactions associated with botulinal antitoxin. Am J Med (1980) 1.74
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst (1990) 1.61
Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine (2001) 1.60
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun (1997) 1.56
Monoclonal antibodies in the clinic. Nat Biotechnol (2001) 1.55
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J Biol Chem (2001) 1.42
Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 1.32
Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun (2001) 1.24
High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun (2001) 1.22
Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis (1996) 1.14
The efficacy of vaccinial immune globulin. A 15-year study. Vox Sang (1976) 1.07
Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol (1993) 1.06
The current use of botulinum toxin. J Clin Neurosci (2000) 1.04
A circular antibody-antigen complex is responsible for increased affinity shown by mixtures of monoclonal antibodies to human chorionic gonadotropin. J Immunol (1983) 0.98
Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes. Vaccine (2000) 0.93
Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Toxicon (2001) 0.93
A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon (1995) 0.93
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 10.90
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell (1987) 7.51
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Airway management for trauma patients with potential cervical spine injuries. Anesth Analg (1991) 4.38
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
Lowry determination of protein in the presence of Triton X-100. Anal Biochem (1975) 3.94
Putative contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes (Lond) (2006) 3.90
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Conditions Affecting Enzyme Synthesis in Cotyledons of Germinating Seeds. Plant Physiol (1960) 3.69
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
A neural theory of binocular rivalry. Psychol Rev (1989) 3.59
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science (1995) 3.46
Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol (2000) 3.46
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol (2000) 3.30
Brain areas involved in perception of biological motion. J Cogn Neurosci (2000) 3.21
The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol (1992) 3.19
Inhibition by acetylene of conventional hydrogenase in nitrogen-fixing bacteria. Nature (1976) 3.11
Telling the truth about terminal cancer. JAMA (1998) 3.07
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
Results of cardiopulmonary resuscitation. Failure to predict survival in two community hospitals. Arch Intern Med (1993) 3.02
Neuronal activity in human primary visual cortex correlates with perception during binocular rivalry. Nat Neurosci (2000) 2.91
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Species identification of coagulase-negative staphylococcal isolates from blood cultures. J Clin Microbiol (1982) 2.71
The anatomic basis of parathyroid surgery. Ann Surg (1976) 2.70
A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A (2000) 2.69
Heat shock proteins are methylated in avian and mammalian cells. Proc Natl Acad Sci U S A (1981) 2.68
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD (2009) 2.61
Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2005) 2.60
Pestivirus translation initiation occurs by internal ribosome entry. Virology (1995) 2.56
Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity (2000) 2.53
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol (1992) 2.43
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol (2011) 2.41
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A (1998) 2.32
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
A highly divergent picornavirus in a marine mammal. J Virol (2007) 2.23
The surgical management of paraduodenal hernia. Ann Surg (1968) 2.20
Bovine interstitial retinol-binding protein (IRBP)--isolation and sequence analysis of cDNA clones, characterization and in vitro translation of mRNA. Vision Res (1986) 2.16
Bgl II RFLP recognized by a human IRBP cDNA localized to chromosome 10. Nucleic Acids Res (1987) 2.15
Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites. Gene (1985) 2.15
Vacuum pack technique of temporary abdominal closure: a 7-year experience with 112 patients. J Trauma (2000) 2.13
Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol (2001) 2.10
V(D)J recombination in Ku86-deficient mice: distinct effects on coding, signal, and hybrid joint formation. Immunity (1997) 2.10
Insuring Latinos against the costs of illness. JAMA (1993) 2.09
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Oldest playable musical instruments found at Jiahu early Neolithic site in China. Nature (1999) 2.08
Human anti-self antibodies with high specificity from phage display libraries. EMBO J (1993) 2.08
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
Emergency abdominal surgery in the aged. Br J Surg (1976) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Intracisternal A-particle genes in Mus musculus: a conserved family of retrovirus-like elements. Mol Cell Biol (1981) 2.07
Structural repertoire of the human VH segments. J Mol Biol (1992) 2.06
Thermodynamics and structure of a DNA tetraplex: a spectroscopic and calorimetric study of the tetramolecular complexes of d(TG3T) and d(TG3T2G3T). Proc Natl Acad Sci U S A (1992) 2.03
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell (1995) 1.99
Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab (2000) 1.99
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med (1998) 1.95
Functional differences between memory and naive CD8 T cells. Proc Natl Acad Sci U S A (1999) 1.94
Data from men in greater Seattle area reveals no downward trend in semen quality: further evidence that deterioration of semen quality is not geographically uniform. Fertil Steril (1996) 1.93
Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation (1999) 1.93
Odontogenic tumors. A demographic study of 759 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1998) 1.93
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol (1996) 1.90
Visual form created solely from temporal structure. Science (1999) 1.87
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int (2008) 1.86
Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. Proc Natl Acad Sci U S A (2007) 1.85
Pumilio is essential for function but not for distribution of the Drosophila abdominal determinant Nanos. Genes Dev (1992) 1.85
Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia (2009) 1.83
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene (2001) 1.82